

Peer Review

Review of: "A Novel Bispecific Antibody CVL006 Superior to AK112 for Dual Targeting of PD-L1 and VEGF in Cancer Therapy"

Yalda Yazdani¹

1. University of California, Irvine, United States

Abstract and introduction:

1-While well-written, the introduction does not explicitly state a clear hypothesis or research question guiding the study.

2- Claims without references: Some claims about the superiority of bispecific antibodies compared to combination therapy are not supported with references.

Background:

1-While AK112 is discussed, the comparison lacks specific quantitative performance metrics (e.g., binding affinity, half-life, safety profile).

2-It is better to provide a **comparative table** summarizing key differences between CVL006 and existing therapies (e.g., AK112, atezolizumab).

Methods:

1-Justify the selection of specific tumor models and experimental conditions.

2-Provide more details on **statistical analysis**, including error margins and corrections for multiple comparisons.

3-Clearly outline the **antibody engineering process** to enhance reproducibility.

Results:

- 1- Conduct and present a direct comparative study with AK112 in the same experimental model.
- 2- Provide detailed explanations of figures in the text.
- 3- Include preliminary toxicity data or reference safety studies.

Discussion

- 1- Include a statistical significance test to support the claim that CVL006 is superior.
- 2- Discuss clinical challenges, such as cost, feasibility of production, and regulatory considerations.
- 3- Address potential resistance mechanisms and strategies to overcome them.

Declarations

Potential competing interests: No potential competing interests to declare.